When compared to the control group, 131I‐ALT‐836 treatment significantly reduced the tumor uptake of IRDye 800CW‐ALT‐836 (Figure S4C,D, Supporting Information), indicating a single administration of 131I‐ALT‐836 substantially saturated and/or downregulated TF expression in the tumors. This evidence concerns the gene TF and neoplasm.